Adicet Bio

ACET · NASDAQ

$4.52−$0.01 (−0.22%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.53

Latest news

Press releaseSep 30, 7:12 PM ETBusiness Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
NewsSep 28, 6:49 AM ET
Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS
Press releaseSep 28, 6:45 AM ETBusiness Wire
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
NewsSep 28, 5:29 AM ETAvi Kapoor
Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Press releaseSep 25, 4:00 PM ETBusiness Wire
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Press releaseSep 1, 7:00 AM ETBusiness Wire
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
Press releaseAug 31, 5:39 PM ETBusiness Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Press releaseAug 27, 4:00 PM ETBusiness Wire
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
Press releaseAug 5, 4:15 PM ETBusiness Wire
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Press releaseAug 3, 8:00 AM ETPRNewswire
Lipocine Appoints Michael J. Grissinger to Board of Directors
Press releaseJul 21, 4:00 PM ETBusiness Wire
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
Press releaseMay 14, 4:00 PM ETBusiness Wire
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Press releaseMay 13, 4:01 PM ETBusiness Wire
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Press releaseMar 12, 4:00 PM ETBusiness Wire
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Press releaseJan 30, 7:00 AM ETBusiness Wire
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
NewsJan 7, 7:14 AM ET
Adicet Bio Extends Cash To 2027 As Enrollment Doubles For Lead Autoimmune Drug
Press releaseJan 7, 7:00 AM ETBusiness Wire
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
NewsJan 6, 1:42 PM ETVandana Singh
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
NewsDec 26, 11:21 AM ETAlex Perry
What's Going On With Adicet Bio Stock Today?
Press releaseDec 26, 8:30 AM ETBusiness Wire
Adicet Bio Announces Reverse Stock Split
Press releaseNov 28, 2:23 PM ETBusiness Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Press releaseNov 5, 4:01 PM ETBusiness Wire
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
NewsNov 4, 4:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseOct 31, 4:59 PM ETBusiness Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Press releaseOct 28, 7:00 AM ETBusiness Wire
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Press releaseOct 16, 7:00 AM ETBusiness Wire
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
NewsOct 7, 11:05 AM ETVandana Singh
Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2
Press releaseOct 7, 7:01 AM ETBusiness Wire
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
Press releaseOct 7, 6:45 AM ETBusiness Wire
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
Press releaseSep 30, 4:27 PM ETBusiness Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Press releaseSep 2, 7:00 AM ETBusiness Wire
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Press releaseAug 29, 4:48 PM ETBusiness Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NewsAug 19, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsMay 9, 8:10 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsMay 8, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS

Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Lipocine Appoints Michael J. Grissinger to Board of Directors

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Adicet Bio Extends Cash To 2027 As Enrollment Doubles For Lead Autoimmune Drug

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

What's Going On With Adicet Bio Stock Today?

Adicet Bio Announces Reverse Stock Split

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

12 Health Care Stocks Moving In Tuesday's After-Market Session

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session